Table 2.
Timing of Diagnosis of Underlying Chronic Inflammatory Diseases and Description of Oral Glucocorticoid Exposure During the Study Period
| Chronic Inflammatory Disease | Diagnosed at Baseline | Diagnosed During Follow-Up | Overall Cumulative Exposure (mg) | Past-y Cumulative Exposure (mg) |
|---|---|---|---|---|
| IBD | 7912 (50.9) | 7627 (49.1) | 4001 (52.8) | 503 (8.2) |
| PMR-GCA | 7374 (22.8) | 24,991 (77.2) | 6049 (33.8) | 910 (6.7) |
| Rheumatoid arthritis | 7838 (46.1) | 9120 (53.8) | 6315 (65.9) | 934 (9.5) |
| SLE | 1210 (54.7) | 1001 (45.3) | 6834 (199.8) | 982 (27.6) |
| Vasculitis | 959 (26.9) | 2606 (73.1) | 6329 (155.5) | 966 (23.9) |
| All diseases | 25,293 (35.8) | 45,345 (64.2) | 5701 (27.2) | 831 (4.5) |
Timing of diagnosis data are shown as n (%); cumulative exposure data are shown as mean (SD) PED.
Abbreviations: IBD, inflammatory bowel disease; PED, prednisolone-equivalent dose; PMR-GCA, polymyalgia rheumatica and/or giant cell arteritis; SLE, systemic lupus erythematosus.